--(www.USEquityNews.com)-- 05/06/2008 - Healthcare industry alert provided by U.S. Equity News. Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced recently that it will report its financial results for the quarter ended March 31, 2008 on Friday, May 9, 2008. C. Randal Mills, Ph.D., President and Chief Executive Officer, will provide a company update and discuss results via a webcast and conference call on Friday, May 9, 2008 at 9:00 a.m. EDT. To access the web cast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (877) 397-0291 (U.S. participants) or (719) 325-4920 (international participants).
Biotechnology company MannKind Corp. (NASDAQ: MNKD) said recently its first-quarter loss narrowed on lower research and development costs. The company lost $71.4 million, or 70 cents per share, compared with a loss of $73.1 million, or $1 per share, during the same period a year prior. Revenue rose to $20,000 from $10,000. During the most recent period, MannKind had about 28 million additional shares of common stock outstanding. Analysts polled by Thomson Financial expected a loss of 79 cents per share, with no revenue.
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) recently announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the treatment of obesity. The objective of this dose-ranging study is to support dose selection for Phase 3, and to inform the ongoing development of a convenient delivery system for this combination regimen. The six-month, randomized, double-blind, placebo-controlled multi-center study will enroll approximately 600 overweight and obese subjects and is expected to complete in mid-2009.
TapImmune Inc. (OTC BB: TPIM) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development program includes phased manufacturing and production for both infectious disease adjuvant and cancer therapeutic vaccine candidates. These will culminate in toxicology studies and will coincide with pre-IND meeting preparation with the FDA and clinical protocols for our proposed phase 1 human studies. This milestone is predicated on the back of a year where we have seen the completion of the UBC assignment agreement finally effecting our acquisition of the core technologies we developed under the world-wide license agreement.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
